Investors are bracing for a pivotal moment for BioNTech SE. The German biotechnology firm is set to release its full-year 2025 financial results on March 10, an ...
Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus areas for 2026, including an ...
All eyes are on the scheduled release of BioNTech's fourth-quarter and full-year 2025 financial results, set for March 10, 2026. The accompanying conference call will occur during a period of intense ...
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2025 on ...
Investors in BioNTech SE are preparing for a key financial update, with the company confirming it will release its fourth-quarter and full-year 2025 results on ...
The release of the fourth quarter and full-year 2025 results will serve as a comprehensive health check, moving beyond quarterly performance to evaluate the company's broader strategic pivot. The core ...
MAINZ, Germany, and ROCKVILLE, USA, December 6, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today presented data from the non-pivotal dose-confirmation ...
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines. Speaking at the J.P. Morgan Healthcare Conference in San Francisco, ...
BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results